Highlights in Multiple Myeloma from the 2016 ASCO Annual Meeting

Immunotherapy, PROs and Prognostication with PET – Sagar Lonial, MD Begin

The Role of Transplant and Doublet vs. Triplet Salvage Therapy – Philippe Moreau, MD Begin

Smoldering Myeloma, Outcomes Predictors, and Checkpoint Inhibitors – Robert Z. Orlowski, MD, PhD Begin

Novel Drugs, Conditioning Regimens, and Induction Therapy – Joshua Richter, MD Begin

Next-Generation Proteasome Inhibitors, MRD and Genetic Plasma Cell Signatures – Edward A. Stadtmauer, MD Begin